Pharmaceutical

PRO-1107 by ProfoundBio Suzhou for Solid Tumor: Likelihood of Approval

PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor.

Apr 21, 2024 - 00:00
PRO-1107 is under clinical development by ProfoundBio Suzhou and currently in Phase II for Solid Tumor.
Read the original article

Tags:

Previous Article

PRO-1107 by ProfoundBio Suzhou for Endometrial Cancer: Likelihood of Approval

Next Article

PRO-1107 by ProfoundBio Suzhou for Bladder Cancer: Likelihood of Approval

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Pharmalittle: We’re reading about Wegovy shipments, the NIH director’s plans, and more

STAT+: Pharmalittle: We’re reading about Wegovy shipmen...

Jan 16, 2024

Polio transmission was supposed to end by 2023. A new report explains why it won’t.

Polio transmission was supposed to end by 2023. A new r...

Sep 16, 2023

STAT+: Medicare official insists drug price negotiation will consider value of drugs

STAT+: Medicare official insists drug price negotiation...

Apr 25, 2023